Ulcerative Colitis Trials

Study Title:

In actiVE ulcerative colitis, a RanDomIzed Controlled Trial for determination of the optimal treatment target.

Study Title:

A 54-Week, Randomized, Double-blind, Placebo-Controlled, Parallel-group Phase 2, Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis.

Study Title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy.

Study Title:
A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Efficacy and Safety of mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis.

Study Title:

A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis.

Study Title:

THE EVALUATION OF INJECTION SITE PAIN AND ADHERENCE IN PATIENTS SWITCHING FROM A LOW TO HIGH CONCENTRATION ADALIMUMAB (AVT-02) ACROSS MULTIPLE INDICATIONS.